Preventing mother-to-child transmission of HIV: The USA experience

Prenatal and Neonatal Medicine

Volumn 4, Issue 5, 1999, Pages 391-397

  Read, J S ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

HIV; Prevention; United States of America; Vertical transmission

Indexed keywords

ARTICLE; HEALTH CARE POLICY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; PATIENT COUNSELING; PRIORITY JOURNAL; UNITED STATES; VERTICAL TRANSMISSION;

EID: 0032761203     PISSN: 13598635     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. 1. CDC. HIV/AIDS Surveillance Report 1997;9:1-43
2. 2. Karon J, Rosenberg PS, McQuillan G, Khare M, Gwinn M, Petersen LR. Prevalence of HIV infection in the United States, 1985-1992. J Am Med Assoc 1996;276: 126-31
3. 3. Byers RH Jr, Caldwell MB, Davis S, Gwinn M, Lindegren ML. Projection of AIDS and HIV incidence among children born infected with HIV. Stat Med 1998; 17:169-81
4. 4. Wortley PM, Fleming PL. AIDS in women in the United States. J Am Med Assoc 1997;278:911-16
5. 5. Rosenberg PS, Biggar RJ. Trends in HIV incidence among young adults in the United States. J Am Med Assoc 1998;279:1894-9
6. 6. Simonds RJ, Steketee R, Nesheim S, et al. Impact of zidovudine use on risk and risk factors for perinatal transmission of HIV. AIDS 1998;12:301-8
7. 7. CDC. Update: perinatally acquired HIV/AIDS - United States. Morbid Mortal Wkly Rep 1997;46:1085-92
8. 8. CDC. Recommendations for assisting in the prevention of perinatal transmission of human T-lymphotropic virus type III/lymphadenopathy-associated virus and acquired immunodeficiency syndrome. Morbid Mortal Wkly Rep 1985; 34:721-6
9. 9. CDC. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbid Mortal Wkly Rep 1994;43:1-20
10. 10. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80
11. 11. CDC. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. Morbid Mortal Wkly Rep 1995;44: 1-15
12. 12. Bertolli JM, Hsu H, Frederick T, et al. Breastfeeding among HIV-infected women, Los Angeles and Massachusetts, 1988-1993. Presented at the 11th World AIDS Conference, Vancouver, July 1996:abstr We.C.3583
13. 13. Fiscus SA, Adimora AA, Schoenbach VJ, Wilfert C, Johnson VA and the North Carolina Children's AIDS Network. Can zidovudine monotherapy continue to reduce perinatal HIV transmission? The North Carolina experience. Presented at the 12th World AIDS Conference, Geneva, June 1998:abstr 33162
14. 14. Bertolli J, Simonds RJ, Thomas P, et al. Implementation of recommendations for the medical care of HIV-exposed infants in the first year of life, USA. Presented at the 12th World AIDS Conference, Geneva, June 1998: abstr 23269
15. 15. CDC. Success in implementing public health service guidelines to reduce perinatal transmission of HIV -Louisiana, Michigan, New Jersey, and South Carolina, 1993, 1995, and 1996. Morbid Mortal Wkly Rep 1998;37:688-91
16. 16. Lazzarini Z, Gostin LO, Ward JW, Fleming PL, Neslund VS. State efforts to reduce perinatal HIV transmission. Presented at the 12th World AIDS Conference, Geneva, June 1998:abstr 44105
17. 17. Ethier K, Fox-Tierney RA, Ickovics JR. Prenatal HIV counseling and testing: rates and determinants among women at public health clinics. Presented at the 12th World AIDS Conference, Geneva, June 1998:abstr 43111
18. 18. Driscoll M, Cormack A, Garcia-Bunuel L, Joo E, Taylor D, Kelly C. A survey of women to determine perinatal provider practice regarding HIV education, counseling and voluntary testing. Presented at the 12th World AIDS Conference, Geneva, June 1998:abstr 43561
19. 19. Minkoff H, Ehrlich I, Feldman J, Holman S, Fazili S, Augenbraum M. Reproductive health hospitalizations among women with human immunodeficiency virus infections. Am J Obstet Cynecol 1998;178:166-70
20. 20. MacDonald SR, Skor A, Socol ML, Garcia PM. Human immunodeficiency virus infection and women: a survey of missed opportunities for testing and diagnosis. Am J Obstet Gynecol 1998;178:1264-71
21. 21. Solomon L, Stein M, Flynn C, et al. Health service use by urban women with or at risk for HIV-1 infection. The HIV Epidemiology Research Study (HERS). J Acquir Immune Defic Syndr Hum Retrovirol 1998;17:253-61
22. 22. Institute of Medicine. Reducing the Odds: Preventing Perinatal Transmission of HIV in the United States. Washington, DC: National Academy Press, 1998
23. 23. Wade NA, Birkhead GS, Warran BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J MeJ 1998;339:1409-14
24. 24. Irwin K, Olivo N, Schable CA, et al. Performance characteristics of a rapid HIV antibody assay in a hospital with a high prevalence of HIV infection. Ann Intern Med 1996;125:471-5
25. 25. Stetler HC, Granade TC, Nunez CA, et al. Field evaluation of rapid HIV serologic tests for screening and confirming HIV-1 infection in Honduras. AIDS 1997;11: 369-75
26. 26. Spielberg F, Kassler W. Rapid testing for HIV antibody: a technology whose time has come. Ann Intern Med 1996;125:509-11
27. 27. Minkoff H, O'Sullivan MJ. The case for rapid HIV testing during labor. J Am Med Assoc 1998;279:1743-4
28. 28. Pacheco-Acosta E, Antonella T, Higgins A, et al. Reproductive choices in the Women and Infant Transmission Study (WITS): pre and post ACTG 076 results. Presented at the 12th World AIDS Conference, Geneva, June 1998:abstr 13565
29. 29. CDC. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV-1 for maternal health and for reducing perinatal HIV-1 transmission in the United States. Morbid Mortal Wkly Rep 1998;47:1-30
30. 30. Dorenbaum-Kracer A, Sullivan J, Gelber R, et al. Antiretroviral use in pregnancy in PACTG 316: a phase III randomized, blinded study of single-dose intrapartum/ neonatal nevirapine to reduce mother to infant HIV transmission. Presented at the 12th World AIDS Conference, Geneva, June 1998:abstr 23281
31. 31. The International Perinatal HIV Group. The mode of delivery and the risk of vertical transmission of human immunodeficiency virus type 1: a meta-analysis of 15 prospective cohort studies. N Engl J Med 1999;340: 977-87
32. 32. The European Mode of Delivery Collaboration. Elective Caesarean section versus vaginal delivery in preventing vertical HIV-1 transmission: a randomised clinical trial. Lancet 1999;353:1035-7
33. 33. American College of Obstetricians and Gynecologists. Scheduled Cesarean delivery and the prevention of vertical transmission of HIV infection. ACOG Committee Opinion Number 219. Washington, DC: ACOG, August 1999
34. 34. American College of Obstetricians and Gynecologists. Human immunodeficiency virus infections in pregnancy. ACOG Educational Bulletin Number 232, January 1997
35. 35. European Collaborative Study. Therapeutic and other interventions to reduce the risk of mother-to-child transmission of HIV-1 in Europe. Br J Obstet Gynaecol 1998;105:704-9